Aktis Oncology (AKTS) Return on Capital Employed [ROCE] (2026)
Aktis Oncology (AKTS) recorded Return on Capital Employed [ROCE] of -20.34% in Q3 2026, down 4.05 percentage points from the prior quarter.
Powered by 
Analysis
Aktis Oncology (AKTS) Return on Capital Employed [ROCE] (2026) Analysis & Trends
For FY2025, Aktis Oncology reported Return on Capital Employed [ROCE] of -28.26%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 35.41% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 17.52% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 21.60% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 4.65% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 9.91% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 17.37% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | -6.15% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 11.32% |
| 10 | Aktis Oncology | 895.95 Mn | 335.72 Mn | - | -20.34% |
API Access
Aktis Oncology Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=AKTS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "AKTS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=AKTS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();